The optimal duration of dual antiplatelet therapy after PCI

Mikkel Malby Schoos, Roxana Mehran, George D. Dangas

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


In parallel with the evolution of the dual antiplatelet therapy (DAPT) regimen, stent technology has matured from bare metal stents (BMS) over first generation to now second generation drug-eluting stents (DES) and improvements in stent technology have direct implications for the clinical strategy of DAPT. The use of newer generation DES has rapidly increased and is currently implanted in approximately 85% of patients undergoing percutaneous coronary intervention (PCI). In patients with acute coronary syndrome (ACS) undergoing PCI, the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines recommend that a P2Y12 inhibitor is maintained over 12 months in addition to aspirin, unless there are contraindications such as excessive risk of bleeding. Seminal trials have delineated the current recommendations on DAPT in patients with and without ACS. Randomized controlled trials (RCT) suggest that shorter durations of DAPT are safe with newer stent platforms.

Original languageEnglish
Title of host publicationInterventional Cardiology
Subtitle of host publicationPrinciples and Practice
Number of pages7
ISBN (Electronic)9781118983652
ISBN (Print)9781118976036
StatePublished - 21 Nov 2016


  • Acute coronary syndrome
  • Atrial fibrillation
  • Bare metal stents
  • Drug-eluting stents
  • Dual antiplatelet therapy
  • Percutaneous coronary intervention
  • Randomized controlled trials
  • Stent technology evolution


Dive into the research topics of 'The optimal duration of dual antiplatelet therapy after PCI'. Together they form a unique fingerprint.

Cite this